PortalPublikationenSuccessful anti-viral treatment improves survival of patient...

Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C

Standard

Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C. / Rutter, K; Stättermayer, A F; Beinhardt, S; Scherzer, T-M; Steindl-Munda, P; Trauner, M; Ferenci, P; Hofer, H.

in: ALIMENT PHARM THER, Jahrgang 41, Nr. 6, 01.03.2015, S. 521-31.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Rutter, K, Stättermayer, AF, Beinhardt, S, Scherzer, T-M, Steindl-Munda, P, Trauner, M, Ferenci, P & Hofer, H 2015, 'Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C', ALIMENT PHARM THER, Jg. 41, Nr. 6, S. 521-31. https://doi.org/10.1111/apt.13085

APA

Rutter, K., Stättermayer, A. F., Beinhardt, S., Scherzer, T-M., Steindl-Munda, P., Trauner, M., Ferenci, P., & Hofer, H. (2015). Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C. ALIMENT PHARM THER, 41(6), 521-31. https://doi.org/10.1111/apt.13085

Vancouver

Rutter K, Stättermayer AF, Beinhardt S, Scherzer T-M, Steindl-Munda P, Trauner M et al. Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C. ALIMENT PHARM THER. 2015 Mär 1;41(6):521-31. https://doi.org/10.1111/apt.13085

Bibtex

@article{fc04ec9e33d74f35aa211ecd68c7da72,
title = "Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C",
abstract = "BACKGROUND: Long-term outcome of chronic hepatitis C patients with successful viral eradication seems to be promising.AIM: To evaluate mortality, incidence of hepatocellular carcinoma (HCC), liver failure and liver transplantation in sustained virological responders (SVR) and non-SVR patients with different stages of fibrosis.METHODS: Seven hundred and fourteen patients with a follow-up of 7.2 (1-21.1) years (age: 51.4 ± 12.0 years, 276 female, IFN-monotherapy: n = 19, IFN/RBV: n = 122, peg-IFN/RBV: n = 573, SVR: 551, non-SVR: 163) were studied. Two hundred and ten of 540 patients with a liver biopsy prior to treatment had advanced stages of fibrosis (Metavir F3/F4).RESULTS: Forty-eight patients died during follow-up, 15 with SVR and 33 without (P < 0.001). Five- and 10-year mortality rates were 1.8% (10/551) and 2.7% (15/551) in the SVR group and 8.6% (14/163) and 19.1% (31/163) in the non-SVR patients (P < 0.001). In 29 patients, decompensation of liver disease [SVR: 9 (1.6%) vs. non-SVR: 20 (12.3%); P < 0.001] occurred and in 29 patients, HCC developed during follow-up [SVR: 10 (1.8%) vs. non-SVR: 19 (11.7%); P < 0.001]. Non-SVR was an independent predictor for developing (i) HCC [HR: 2.36 (95% CI: 1.07-5.23; P = 0.034], (ii) liver-related complications [HR: 2.62; (95% CI: 1.18-5.81; P = 0.018] and (iii) mortality (HR: 3.46; 95% CI: 1.91-6.29; P < 0.001). For patients with early stages of fibrosis (F0-F2), a survival benefit of SVR patients could not be demonstrated.CONCLUSIONS: Successful anti-viral therapy decreases mortality, incidence of hepatocellular carcinoma and liver failure in patients with advanced fibrosis. However, hepatocellular carcinoma development or liver failure are not prevented completely, and further follow-up of patients is advisable.",
author = "K Rutter and St{\"a}ttermayer, {A F} and S Beinhardt and T-M Scherzer and P Steindl-Munda and M Trauner and P Ferenci and H Hofer",
note = "{\textcopyright} 2015 John Wiley & Sons Ltd.",
year = "2015",
month = mar,
day = "1",
doi = "10.1111/apt.13085",
language = "English",
volume = "41",
pages = "521--31",
journal = "ALIMENT PHARM THER",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "6",

}

RIS

TY - JOUR

T1 - Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C

AU - Rutter, K

AU - Stättermayer, A F

AU - Beinhardt, S

AU - Scherzer, T-M

AU - Steindl-Munda, P

AU - Trauner, M

AU - Ferenci, P

AU - Hofer, H

N1 - © 2015 John Wiley & Sons Ltd.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - BACKGROUND: Long-term outcome of chronic hepatitis C patients with successful viral eradication seems to be promising.AIM: To evaluate mortality, incidence of hepatocellular carcinoma (HCC), liver failure and liver transplantation in sustained virological responders (SVR) and non-SVR patients with different stages of fibrosis.METHODS: Seven hundred and fourteen patients with a follow-up of 7.2 (1-21.1) years (age: 51.4 ± 12.0 years, 276 female, IFN-monotherapy: n = 19, IFN/RBV: n = 122, peg-IFN/RBV: n = 573, SVR: 551, non-SVR: 163) were studied. Two hundred and ten of 540 patients with a liver biopsy prior to treatment had advanced stages of fibrosis (Metavir F3/F4).RESULTS: Forty-eight patients died during follow-up, 15 with SVR and 33 without (P < 0.001). Five- and 10-year mortality rates were 1.8% (10/551) and 2.7% (15/551) in the SVR group and 8.6% (14/163) and 19.1% (31/163) in the non-SVR patients (P < 0.001). In 29 patients, decompensation of liver disease [SVR: 9 (1.6%) vs. non-SVR: 20 (12.3%); P < 0.001] occurred and in 29 patients, HCC developed during follow-up [SVR: 10 (1.8%) vs. non-SVR: 19 (11.7%); P < 0.001]. Non-SVR was an independent predictor for developing (i) HCC [HR: 2.36 (95% CI: 1.07-5.23; P = 0.034], (ii) liver-related complications [HR: 2.62; (95% CI: 1.18-5.81; P = 0.018] and (iii) mortality (HR: 3.46; 95% CI: 1.91-6.29; P < 0.001). For patients with early stages of fibrosis (F0-F2), a survival benefit of SVR patients could not be demonstrated.CONCLUSIONS: Successful anti-viral therapy decreases mortality, incidence of hepatocellular carcinoma and liver failure in patients with advanced fibrosis. However, hepatocellular carcinoma development or liver failure are not prevented completely, and further follow-up of patients is advisable.

AB - BACKGROUND: Long-term outcome of chronic hepatitis C patients with successful viral eradication seems to be promising.AIM: To evaluate mortality, incidence of hepatocellular carcinoma (HCC), liver failure and liver transplantation in sustained virological responders (SVR) and non-SVR patients with different stages of fibrosis.METHODS: Seven hundred and fourteen patients with a follow-up of 7.2 (1-21.1) years (age: 51.4 ± 12.0 years, 276 female, IFN-monotherapy: n = 19, IFN/RBV: n = 122, peg-IFN/RBV: n = 573, SVR: 551, non-SVR: 163) were studied. Two hundred and ten of 540 patients with a liver biopsy prior to treatment had advanced stages of fibrosis (Metavir F3/F4).RESULTS: Forty-eight patients died during follow-up, 15 with SVR and 33 without (P < 0.001). Five- and 10-year mortality rates were 1.8% (10/551) and 2.7% (15/551) in the SVR group and 8.6% (14/163) and 19.1% (31/163) in the non-SVR patients (P < 0.001). In 29 patients, decompensation of liver disease [SVR: 9 (1.6%) vs. non-SVR: 20 (12.3%); P < 0.001] occurred and in 29 patients, HCC developed during follow-up [SVR: 10 (1.8%) vs. non-SVR: 19 (11.7%); P < 0.001]. Non-SVR was an independent predictor for developing (i) HCC [HR: 2.36 (95% CI: 1.07-5.23; P = 0.034], (ii) liver-related complications [HR: 2.62; (95% CI: 1.18-5.81; P = 0.018] and (iii) mortality (HR: 3.46; 95% CI: 1.91-6.29; P < 0.001). For patients with early stages of fibrosis (F0-F2), a survival benefit of SVR patients could not be demonstrated.CONCLUSIONS: Successful anti-viral therapy decreases mortality, incidence of hepatocellular carcinoma and liver failure in patients with advanced fibrosis. However, hepatocellular carcinoma development or liver failure are not prevented completely, and further follow-up of patients is advisable.

U2 - 10.1111/apt.13085

DO - 10.1111/apt.13085

M3 - SCORING: Journal article

C2 - 25616017

VL - 41

SP - 521

EP - 531

JO - ALIMENT PHARM THER

JF - ALIMENT PHARM THER

SN - 0269-2813

IS - 6

ER -